This technology is a treatment for cardiac arrhythmias that utilizes gene editing in the phosphorylation sites of the Rad gene.
Calcium ion channels have various effects on cardiac function and muscle contraction. Dysregulation of these channels, potentially due to genetic defects, can cause or exacerbate cardiac arrhythmia syndromes. Current treatments for cardiac arrhythmias include medications, implantable devices, and surgical procedures designed to regulate heart rhythm. However, anti-arrhythmic drugs like beta-blockers are non-specific, resulting in many off-target effects.
This technology is a potential universal therapy for cardiac arrhythmias that leverages gene editing of phosphorylation sites in the Rad gene to prevent its phosphorylation. Inhibition of Rad phosphorylation has been shown to induce an anti-arrhythmic effect through suppressing the adrenergic regulation of the calcium current. This approach is more specific than current anti-arrhythmic drugs, reducing off-target side effects.
IR CU24243
Licensing Contact: Joan Martinez
